Eicosanoid regulation of angiogenesis in tumors

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 1, 2004, Pages 119-125

  Nie, Daotai ^a   Honn, Kenneth V ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Arachidonic acid; Cancer; Eicosanoids; Nonsteroidal anti inflammatory drugs

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYTOCHROME P450; ICOSANOID; LIPID; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ANGIOGENESIS; BLOOD VESSEL; CANCER CELL; CAPILLARY; GENE OVEREXPRESSION; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; VASCULARIZATION;

EICOSANOIDS; HUMANS; LIPOXYGENASE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 1842503012     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822976     Document Type: Review

References (91)

1. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000;92:94-95
2. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364
4. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8
5. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997;14:1495-1502
6. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by P53 regulation of thromobspondin-1. Science 1994;265:1582-1584
7. Rak J, Mitsubishi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction or inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580
8. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275
9. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845
10. Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995;92:768-772
11. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848
12. Forsythe JA, Jiang BH, Iyeer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613
13. Hartmann A, Kunz M, Kostlin S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578-1583
14. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998;251:287-290
15. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-10825
16. Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149:29-40
17. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875
18. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931
19. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000;69:145-182
20. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-4362
21. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990
22. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005
23. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001
24. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764
25. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998;69:168-172
26. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460
27. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-4820
28. DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygcnase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-1262
29. Gustafson-Svard C, Lilja I, Hallbook O, et al. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84
30. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559
31. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Cancer 2000;42:73-78
32. Tremblay C, Dore M, Bochsler PN, et al. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J Natl Cancer Inst 1999;91:1398-1403
33. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-1118
34. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994
35. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204
36. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-2934
37. Subbaramaiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-18657
38. Tsujii M, Kawano S, DuBois RN. Cyclooxygcnase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340
39. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-4249
40. Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999;17:687-694
41. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825
42. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594
43. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716
44. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477
45. Tamura M, Sebastian S, Gurates B, et al. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab 2002;87:3504-3507
46. Hull MA, Thomson JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999;45:529-536
47. Pourtau J, Mirshahi F, Li H, et al. Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M. FEBS Lett 1999;459:453-457
48. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423
49. Yamada M, Kawai M, Kawai Y, et al. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 1999;19:300-304
50. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol 1978;86:455-461
51. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-482
52. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218
53. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1 alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002;277:50081-50086
54. Amano H, Hayashi I, Endo H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-232
55. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999;274:17042-17048
56. Xin X, Yang S, Kowalski J, et al. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121
57. 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 2000;267:245-251
58. Daniel TO, Liu H, Morrow JD, et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-4577
59. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 1999;274:35562-35570
60. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002;161:421-428
61. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998;95:13182-13187
62. Tong WG, Ding XZ, Witt RC, et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002;1:929-935
63. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999;274:23679-23682
64. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 1997;94:6148-6152
65. Shappell SB, Gupta RA, Manning S, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001;61:497-503
66. Jack GS, Brash AR, Olson SJ, et al. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2000;31:1146-1154
67. Shappell SB, Boeglin WE, Olson SJ, et al. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999;155:235-245
68. Gao X, Grignon DJ, Chbihi T, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995;46:227-237
69. Ding XZ, Iversen P, Cluck MW, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 1999;261:218-223
70. Natarajan R, Esworthy R, Bai W, et al. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab 1997;82:1790-1798
71. Natarajan R, Nadler J. Role of lipoxygenases in breast cancer. Front Biosci 1998;3:E81-E88
72. Connolly JM, Rose DP. Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett 1998;132:107-112
73. Chen YQ, Duniec ZM, Liu B, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 1994;54:1574-1579
74. Hong SH, Avis I, Vos MD, et al. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999;59:2223-2228
75. Hagmann W, Gao X, Zacharek A, et al. 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes. Prostaglandins 1995;49:49-62
76. Liu B, Marnett LJ, Chaudhary A, et al. Biosynthesis of 12(S)-Hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential. Lab Invest 1994;70:314-323
77. Chang WC, Liu YW, Ning CC, et al. Induction of arachidonate 12-lipoxygenase mRNA by epidermal growth factor in A431 cells. J Biol Chem 1993;268:18734-18739
78. Chen BK, Kung HC, Tsai TY, et al. Essential role of mitogen-activated protein kinase pathway and c-Jun induction in epidermal growth factor-induced gene expression of human 12-lipoxygenase. Mol Pharmacol 2000;57:153-161
79. Silletti S, Timar J, Honn KV, et al. Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants. Cancer Res 1994;54:5752-5756
80. Chen BK, Chang WC. Overexpression of c-Fos enhances the transcription of human arachidonate 12-lipoxygenase in A431 cells. Biochem Biophys Res Commun 1999;261:848-852
81. Nie D, Hillman GG, Geddes T, et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998;58:4047-1051
82. 3 integrins on endothelial cells. Int J Cancer 1993;54:102-111
83. Tang DG, Chen YQ, Renaud C, et al. Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitro-nectin receptor and fibronectin receptor. J Cell Biol 1993;121:689-704
84. 3 integrin: a post-transcriptional, PKC- and cytoskeleton-dependent process. Cancer Res 1994;54:1119-1129
85. 3 protein kinase C activator 12(S)-HETE. J Cell Sci 1995;108:2629-2644
86. 3 for angiogenesis. Science 1994;264:569-571
87. Honn KV, Grossi IM, Diglio CA, et al. Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE induced endothelial cell retraction. FASEB J 1989;3:2285-2293
88. 3 integrins. Prostaglandins 1993;45:249-268
89. Honn KV, Tang DG, Grossi I, et al. Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res 1994;54:565-574
90. Tang DG, Renaud C, Stojakovic S, et al. 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun 1995;211:462-468
91. Setty BNJ, Graeber JE, Stuart MJ. The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition. J Biol Chem 1987;262:17613-17622